Furthermore, in PC progression, ANXA1 has been already associated to a strong oncogenic action mainly interacting with FPR receptor partner family when in the intracellular environment and also as extracellular counterpart [12,15,20,51,52,53] acting in an autocrine and paracrine manner. The gene discussed is ANXA1; the disease is pachyonychia congenita.